Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 2/20 | 0.69 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 5/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.40 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.40 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.40 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16660929 | 0.81 | DGAT1 (1.00) | DGAT1NAPRTRAB9ASMN1; SMN2POLB | |
| SCHEMBL5491825 | 0.80 | DGAT1 (0.54) | DGAT1NAPRTRAB9ASMN1; SMN2POLB | |
| SCHEMBL12204514 | 0.78 | HDAC1 (0.52) | DGAT1POLBKMT2AMEN1L3MBTL1 | |
| SCHEMBL19724261 | 0.78 | DGAT1 (0.59) | DGAT1NAPRTRAB9ASMN1; SMN2POLB | |
| SCHEMBL29552438 | 0.77 | MAPK1 (0.65) | DGAT1NAPRTRAB9ASMN1; SMN2POLB | |
| SCHEMBL3698000 | 0.77 | DGAT1 (0.54) | DGAT1NAPRTRAB9ASMN1; SMN2POLB | |
| SCHEMBL64640 | 0.77 | MAPK1 (0.65) | DGAT1NAPRTRAB9ASMN1; SMN2POLB | |
| SCHEMBL22230069 | 0.77 | DGAT1 (0.42) | DGAT1L3MBTL1MAPT | |
| SCHEMBL20241211 | 0.76 | MAPK1 (0.62) | DGAT1NAPRTRAB9ASMN1; SMN2POLB | |
| SCHEMBL29776105 | 0.76 | MAPK1 (0.62) | DGAT1NAPRTRAB9ASMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4041393-B1 | NOVEL HETEROARYL-TRIAZOLE COMPOUNDS AS PESTICIDES | BAYER AG (DE) | 2026-04-08 | — | — | EP | disclosed |
| CN-114867529-B | Novel heteroaryl triazole compounds as pesticides | 拜耳公司 | 2024-09-27 | — | — | CN | disclosed |
| CN-117567338-A | Novel heteroaryl triazole compounds as pesticides | 拜耳公司 | 2024-02-20 | — | — | CN | disclosed |
| US-20230028441-A1 | NOVEL HETEROARYL-TRIAZOLE COMPOUNDS AS PESTICIDES | ELANCO ANIMAL HEALTH GMBH (DE) | 2023-01-26 | — | — | US | disclosed |
| EP-4041393-A1 | NOVEL HETEROARYL-TRIAZOLE COMPOUNDS AS PESTICIDES | Bayer Aktiengesellschaft (DE) | 2022-08-17 | — | — | EP | disclosed |
| CN-114867529-A | Novel heteroaryl triazole compounds as pesticides | 拜耳公司 | 2022-08-05 | — | — | CN | disclosed |
| WO-2021069567-A1 | NOVEL HETEROARYL-TRIAZOLE COMPOUNDS AS PESTICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 2021-04-15 | — | — | WO | disclosed |
| EP-2260031-B1 | COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME (US) | 2015-10-07 | — | — | EP | disclosed |
| EP-2260031-B1 | COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME (US) | 2015-10-07 | — | — | EP | disclosed |
| US-8716483-B2 | Compounds that are ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-05-06 | — | — | US | disclosed |
| US-20110189192-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME LLC | 2011-08-04 | — | — | US | disclosed |
| EP-2260031-A1 | COMPOUNDS THAT ARE ERK INHIBITORS | Schering Corporation (US) | 2010-12-15 | — | — | EP | disclosed |
| WO-2009105500-A1 | COMPOUNDS THAT ARE ERK INHIBITORS | SCHERING CORPORATION (US) | 2009-08-27 | — | — | WO | disclosed |
| WO-2009105500-A1 | COMPOUNDS THAT ARE ERK INHIBITORS | SCHERING CORPORATION (US) | 2009-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110189192-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MAPK1, MAPK4, MAPK10 | DGAT1 1976/4885NAPRT 1618/4885RAB9A 287/4885 |
| US-20230028441-A1 | NOVEL HETEROARYL-TRIAZOLE COMPOUNDS AS PESTICIDES | PRXL2A, GLRX3, CYP4F3 | DGAT1 3177/4885NAPRT 3878/4885RAB9A 744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.